Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 127 clinical trials
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

SUNNIFORECAST (Sunitinib vs. Nivolumab + Ipilimumab as First line treatment Of REnal cell CAncer of non-clear cell SubTypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell …

vasectomy
measurable disease
clear cell renal cell carcinoma
nivolumab
platelet count
University Hospital Erlangen
 (8.7 away) Contact site
  • 116 views
  • 25 Jan, 2021
  • +40 other locations
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

left bundle branch block
cardiac resynchronization therapy
medical therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 100 views
  • 16 Feb, 2021
  • +68 other locations
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced melanoma. The primary study hypotheses are that: 1) The combination …

braf v600 mutation
pembrolizumab
interferon
BRAF
systemic therapy
Universitaetsklinikum Erlangen ( Site 0044)
 (8.7 away) Contact site
  • 150 views
  • 16 Jun, 2021
  • +125 other locations
A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas. In this part of the study, tissue samples are taken from patients. The second part of …

prednisone
stem cell transplantation
methotrexate
azathioprine
thiopurines
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 13 views
  • 13 Jun, 2021
  • +18 other locations
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first …

systemic therapy
apremilast
topical agents
cc-10004
phototherapy
Universitatsklinikum Erlangen
 (9.5 away) Contact site
  • 98 views
  • 13 Jun, 2021
  • +282 other locations
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with chemotherapy plus pembrolizumab. Olaparib …

pembrolizumab
taxane
measurable disease
anthracyclines
breast cancer
Universitaetsklinikum Erlangen ( Site 1201)
 (8.7 away) Contact site
  • 241 views
  • 10 Jun, 2021
  • +131 other locations
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687 subjects will be randomized to one of the following treatment arms in …

fruquintinib
irinotecan
regorafenib
vascular endothelial growth factor
colorectal adenocarcinoma
Universitaetsklinikum Erlangen
 (8.7 away) Contact site
  • 0 views
  • 30 Apr, 2021
  • +138 other locations
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody

metastatic merkel cell carcinoma
avelumab
Universit tsklinikum Erlangen
 (9.4 away) Contact site
  • 0 views
  • 15 Jun, 2021
  • +44 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

HER2
cyclophosphamide
paclitaxel
progesterone
epidermal growth factor receptor
Universitaetsklinikum Erlangen ( Site 1001)
 (8.7 away) Contact site
  • 188 views
  • 18 Jun, 2021
  • +285 other locations
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of …

ustekinumab
tumor necrosis factor
abdominal pain
crohn's disease
tumour necrosis
Universitaetsklinikum Erlangen /ID# 223404
 (8.7 away) Contact site
  • 97 views
  • 18 Jun, 2021
  • +383 other locations